Novel gene therapy PS-002 targets podocytes in IgA nephropathy

IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis.

Revive Therapeutics Provides Corporate Update | Psychedelic Invest

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused

March 13, 2024

Legend Biotech’s deal with Novartis is a reminder that biotech’s bear market has a few haves, and many have-nots

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here

November 14, 2023

Expanding treatment horizons for hypermutated urothelial carcinomas beyond immunotherapy

A new editorial paper was published in Oncoscience (Volume 11) on April 25, 2024, entitled, “Therapeutic opportunities for hypermutated urothelial carcinomas beyond immunotherapy.”

May 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.